Although the mechanism by which high HSP90α was associated with poor PFS and OS in advanced lung cancer patients treated with PD-1/PD-L1 inhibitors plus chemotherapy remains unknown, there were some plausible explanations. This evidence concerns the gene HSP90AA1 and lung carcinoma.